We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Chip is a savings and investment portal. The company has over 250,000 registered users, processed over £165 million in savings, achieved Financial Conduct Authority (FSA) authorisation and launched Financial Services Compensation Scheme (FSCS) eligible interest accounts with market-leading rates. It aims to be the go to investment platform for the mobile generation that consists of 100 million customers and 30 trillion assets across Europe. Chip started with autosaving and seamless access to market-leading saving accounts. With its premium account ChipX, the company is venturing into investment funds, savings accounts, and pensions. It will use the investment to open up its investor community to new and existing investors to participate in this convertible round. It will also initiate discussions with venture capitalists to secure a follow up investment.
days to go: Expired investment: £11,403,860
Squirrel is a Barclays-held account that splits your salary up into your bills, savings, and a weekly allowance to spend on whatever you like.
days to go: Expired investment: £503,100
Amino focuses on targeted nutrition using amino acids to improve human health, emphasizing the untapped potential beyond sports and bodybuilding. Currently offering pre- and intra-workout amino acid drinks, the company aims to expand its product line to cater to a broader consumer base, believing the market lacks variety in ready-to-mix powdered blends. Backed by scientific research and a commitment to taste and accessibility, Amino aspires to emerge as the leading global brand in amino acid products.
days to go: Expired investment: £193,219
Decimal Factor arranges payments and lends to small and medium-sized businesses with stable funding. The company is working on open-banking-enabled data capture to build a digital campaign with portals, applications and merchant management tools. The company aims to use cloud-based technology to make payments. The funds will be used for marketing, technology, operations and management.

Pitch Rated

64%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £860,387
A FCA-authorised and regulated digital credit card on smartphones, for those with modern and busy lifestyles. Jaja aims to offer a fair and transparent banking service that gives consumers greater confidence, control and freedom over their finances. The company has tested their app and card with Visa and has partnered with Asda to offer online credit instantly. Jaja's business model allows revenue to be generated via interest payments from revolving lines of credit. Two products will be offered to consumers; the Jaja Credit Card and Jaja Pay. Both will be suitable for B2B and B2C operations. Investments will be used to launch a beta round for 5,000 users to build a community before the products are publicly released. In addition, Jaja intends to expand its customer service team and produce marketing campaigns for their business.
days to go: Expired investment: £4,957,534
Driftrock are a digitasl media media marketing company who specialise in creating simple easy to use advertising tools.
days to go: Expired investment: £800,278
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph